Germantown, Md. & HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
The MHRA has approved Siiltibcy, a new skin test that uses recombinant proteins to more accurately detect tuberculosis in ...
Tuberculosis (TB) remains a persistent challenge to global public health, claiming nearly 1.5 million lives each year. Screening populations at risk for latent TB infection has emerged as a vital ...
Jan. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved a test to identify individual patient variations in drug metabolism; an implant system that simplifies the arthroscopic ...
Qiagen ($QGEN) pointed to a head-to-head comparison study in The Lancet showing that its Quantiferon-TB Gold tuberculosis test could be more accurate at detecting ...
To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback